Roquefort Therapeutics plc (LON:ROQ – Get Free Report) traded up 0.4% on Monday . The stock traded as high as GBX 3.99 ($0.05) and last traded at GBX 3.99 ($0.05). 17,350 shares were traded during mid-day trading, a decline of 97% from the average session volume of 516,817 shares. The stock had previously closed at GBX 3.97 ($0.05).
Roquefort Therapeutics Stock Performance
The business has a 50 day moving average of GBX 4.01 and a 200-day moving average of GBX 4.25. The company has a market capitalization of £5.14 million, a P/E ratio of -395.50 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.
About Roquefort Therapeutics
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
Featured Stories
- Five stocks we like better than Roquefort Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- What Are Dividend Achievers? An Introduction
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Industrial Products Stocks Investing
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
